Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Optimizing the Frontline Management of High-Risk CLL

August 16th 2021

After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.

Optimal Approaches to Bridging Therapy in DLBCL

August 16th 2021

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

Evaluating CAR T Therapies in Lymphoma

August 16th 2021

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

Making the Most of Therapeutic Options in Multiple Myeloma

August 13th 2021

Krina K. Patel, MD, MSc, discusses the use of CAR T-cell therapy in multiple myeloma, potential target antigens beyond BCMA, the rich research landscape, and the role of quadruplets and radiation therapy.

Updates in the Treatment of Waldenström Macroglobulinemia

August 13th 2021

This article discusses the current treatment landscape and therapeutic strategies for Waldenström macroglobulinemia, the role of Bruton tyrosine kinase inhibitor therapies in WM, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Duvelisib Induces Encouraging ORR in Relapsed/Refractory Peripheral T-Cell Lymphoma

August 13th 2021

Duvelisib monotherapy demonstrated encouraging efficacy for patients with relapsed/refractory peripheral T-cell lymphoma.

HMAs in High-Risk MDS

August 13th 2021

The panel of experts comment on the optimal timing of hypomethylating agents and transplant in patients with high-risk myelodysplastic syndrome.

Zandelisib Plus Rituximab Under Study in Indolent Non-Hodgkin Lymphoma

August 13th 2021

Zandelisib plus rituximab is being evaluated as a potentially chemotherapy-free treatment strategy vs standard chemoimmunotherapy in patients with indolent non-Hodgkin lymphoma in first relapse in the ongoing, phase 3 COASTAL trial.

Use of HMAs for the Treatment of MDS

August 13th 2021

The panel of experts highlight the risk factors and considerations for use of hypomethylating agents in patients with myelodysplastic syndrome versus acute myeloid leukemia.

Dr. Zeidner on Transformation to AML in Higher-Risk MDS

August 12th 2021

Joshua F. Zeidner, MD, discusses the risk of transformation to acute myeloid leukemia in higher-risk myelodysplastic syndromes.

Zanubrutinib Shows Encouraging Tolerability, Activity in BTK Inhibitor–Intolerant B-Cell Malignancies

August 12th 2021

Zanubrutinib demonstrated clinical activity and tolerability in previously treated patients with B-cell malignancies who were intolerant to therapy with ibrutinib and/or acalabrutinib, according to results of the phase 2 BGB-3111-215 trial.

Combination Approaches Targeting FLT3 and IDH Mutations

August 12th 2021

Expert hematologist-oncologists share insights into clinical trials studying how to best combine or sequence FLT3 and IDH inhibitors in patients with both mutations.

Toxicities Associated With IDH Inhibitors

August 12th 2021

A panel of key opinion leaders in acute myeloid leukemia reflects on the importance of considering the toxicity profiles of IDH inhibitors and emphasizes the challenges of diagnosing differentiation syndrome.

High-Risk MDS: Prognostic and Predictive Factors

August 12th 2021

Mikkael A. Sekeres, MD, explores prognostic and predictive factors inherent to high-risk MDS, including age and molecular abnormalities.

MDS: Risk Assessment Tools

August 12th 2021

Yazan Madanat, MD, discusses available MDS risk assessment tools and provides insight into his preferred clinical assessment methods.

Loncastuximab Tesirine and Ibrutinib Combination Shows Promise in R/R DLBCL and MCL

August 11th 2021

The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

Optimal Frontline Hodgkin Lymphoma Treatment Requires Careful Consideration of Toxicities

August 11th 2021

Alison J. Moskowitz, MD, discusses recent developments made in the Hodgkin lymphoma paradigm, shared advice for optimal stratification, and spotlighted potential emerging prognostic markers that might further help to guide treatment decisions.

MRD Testing in ALL

August 10th 2021

An overview of the treatment implications of testing for minimal residual disease in pediatric and AYA patients with ALL.

Choosing a Treatment Setting for Patients With ALL

August 10th 2021

Drs Aldoss and McCloskey share their thoughts on treating patients with ALL at community centers versus at tertiary, academic medical centers.

Key Clinical Data for Frontline Targeted Therapy in CLL

August 9th 2021

Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.